1. Home
  2. PSF vs IFRX Comparison

PSF vs IFRX Comparison

Compare PSF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Select Preferred and Income Fund Inc.

PSF

Cohen & Steers Select Preferred and Income Fund Inc.

SELL

Current Price

$17.97

Market Cap

222.3M

Sector

Finance

ML Signal

SELL

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.05

Market Cap

225.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSF
IFRX
Founded
2010
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
222.3M
225.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PSF
IFRX
Price
$17.97
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $8.29
AVG Volume (30 Days)
74.0K
★ 1.1M
Earning Date
01-01-0001
11-03-2026
Dividend Yield
★ 7.69%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.80
$0.80
52 Week High
$20.67
$2.95

Technical Indicators

Market Signals
Indicator
PSF
IFRX
Relative Strength Index (RSI) 38.29 27.04
Support Level $17.81 $0.81
Resistance Level $19.48 $1.07
Average True Range (ATR) 0.33 0.15
MACD -0.09 -0.02
Stochastic Oscillator 6.06 0.00

Price Performance

Historical Comparison
PSF
IFRX

About PSF Cohen & Steers Select Preferred and Income Fund Inc.

Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: